Sandoz Signs a Non-Exclusive License Agreement with AbbVie for IPR of its Humira (adalimumab) for Major EU Countries
Shots:
- Sandoz will hold IPR of Humira in certain countries and will also pay royalties to AbbVie. In response AbbVie will not make any payments to Sandoz
- Humira’s license period for Sandoz in EU and the US will begin on 16 Oct- 2018 and 30 Sep- 2023 respectively
- Hyrimoz (adalimumab- biosimilar) is Sandoz’s seventh biosimilar recently approved in EU including Norway- Iceland and Liechtenstein
Ref: Sandoz | Image:Abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
